The first two mechanisms mentioned could be related to hyperthyroidism propension because TAS2R agonists such as propylthiouracil, approved for hyperthyroidism treatment [24,29], can inhibit TPO [21] and type 1 deiodinase activity [30,31,32]. The gene discussed is TPO; the disease is hyperthyroidism.